Wednesday, January 20, 2021 12:37:37 PM
Avadomide induces type I and II IFN signaling in T cells, triggering a feedforward cascade of reinvigorated anti-CLL immune responses.
IFN-driven promotion of a CD8+ T cell-inflamed microenvironment by avadomide enhances anti-PD-L1/PD-1 efficacy in preclinical models.
https://ashpublications.org/blood/article/137/2/216/464124/Triggering-interferon-signaling-in-T-cells-with
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM